Objective: To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic drug for the treatment of Parkinson disease (PD) when given as monotherapy.
control, rasagiline, that was included in one of the trials makes it difficult to interpret the results. 13 Selective A 2A receptor antagonists administered by themselves have been shown to improve motor disability in rodent and nonhuman primate experimental models of PD, suggesting that they could be effective when used as monotherapy in patients with early PD. 10, 11, 14, 15 The only adequately sized monotherapy trial of a selective A 2A receptor antagonist to date did not find a significant effect of istradefylline over 12 weeks on motor function compared with placebo, although there was a numerical improvement. 16 Here we report the results of a trial of preladenant given as monotherapy in patients with early PD. Rasagiline, an MAO-B inhibitor with established efficacy as monotherapy, was used as an active control. 17, 18 The primary objective of the trial was to demonstrate efficacy of preladenant over placebo.
METHODS Participants. Participants were enrolled at 153 sites in the Americas, Europe, South Africa, India, and Turkey from October 2010 to August 2013. Eligible participants were adults diagnosed with idiopathic PD according to the UK PD Society Brain Bank criteria, 19 and confirmed by the presence of at least 2 of the cardinal signs (bradykinesia, muscular rigidity, and resting tremor). If resting tremor was not present, rigidity or bradykinesia had to be asymmetric; furthermore, a diagnosis based solely on bradykinesia and postural instability was considered insufficient. Participants had disease severity no greater than Hoehn & Yahr stage 3 and Unified Parkinson's Disease Rating Scale (UPDRS) part 3 (motor function) score of $10 at screening. 20 Key exclusion criteria included drug-induced or atypical parkinsonism, prior surgery for PD, cognitive impairment (Montreal Cognitive Assessment score , 22) , 21 untreated major depressive disorder (DSM-IV criteria 22 or a Beck Depression Inventory II score $19), 23 impulse control disorders, hallucinations, and other significant conditions that could interfere with assessments or participation (e.g., psychotic disorder, stroke, and head injury). Eligible participants had not taken L-dopa or dopamine agonists for 30 days or more. Participants receiving anticholinergics or amantadine at a stable dosage for at least the 5 weeks immediately prior to screening were eligible. Those who had taken MAO inhibitors, including rasagiline, within 30 days prior to randomization were not eligible.
Design and study treatment. This was a randomized, doubleblind, parallel-group, multicenter trial, conducted in 2 parts of 26 weeks each. In part 1, participants were randomized 1:1:1:1:1 to preladenant 2, 5, or 10 mg twice daily, rasagiline 1 mg (activecontrol) once daily, or placebo. The primary research question was whether preladenant compared with placebo improves activities of daily living plus motor function in patients with early PD. In part 2, participants treated with placebo in part 1 were switched to preladenant 5 mg twice daily while the others remained on their part 1 treatment; the placebo/preladenant group was intended as a delayed start group for exploratory efficacy comparison to the 5 mg preladenant/preladenant group to assess potential disease-modifying effects if efficacy was demonstrated in part 1.
During the trial, initiation of PD treatments beyond those used at baseline was strongly discouraged. However, if a participant developed an urgent need during the trial, PD treatments (amantadine, anticholinergics, dopaminergic therapy) could be prescribed.
Participants were assigned to treatment using a computergenerated randomized allocation schedule prepared by Merck and implemented through an interactive voice response system. Randomization was stratified by history of L-dopa/dopamine agonist use (none vs ,30 days). Investigators, site staff, participants, and monitoring staff remained blinded to treatment allocation throughout the trials.
Standard protocol approvals, registrations, and patient consents. The trial was conducted in accordance with principles of Good Clinical Practice, and was approved by appropriate institutional review boards and regulatory agencies. All participants provided written informed consent. This trial is registered in clinicaltrials.gov NCT01155479, Merck Protocol MK-3814-024.
Assessments. Participants were examined at screening, baseline (day 1 prior to randomization), and 2, 4, 8, 16, and 26 weeks after randomization. At each examination, the investigator rated the participants with the UPDRS 20 including mental function (part 1), activities of daily living (part 2), motor function (part 3), and complications of therapy (part 4). The person administering the UPDRS was experienced in its use and underwent further training and testing for the trial. As far as possible, the UPDRS was administered by the same experienced qualified rater for a given participant across clinic visits.
Safety was assessed by review of adverse events (AEs), laboratory values, vital signs, and ECGs in all participants who took treatment. Hepatic function was a particular focus since elevated liver function tests (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were observed in previous preladenant studies at higher doses than evaluated here.
Statistical analysis. The primary outcome was change from baseline in the sum of UPDRS parts 2 and 3 scores (UPDRS 213 ). This endpoint has been used in several de novo trials with dopamine agonists. 24, 25 The primary hypothesis was that at least preladenant 10 mg is superior to placebo as measured by the change from baseline to week 26 in UPDRS 213 . The primary efficacy endpoint was analyzed using a constrained longitudinal data analysis approach with treatment, time, treatment-by-time interaction, strata, and participant effects in the model. The least squares mean response and pairwise differences between preladenant doses and placebo, along with 95% confidence intervals (CI), are reported. A comparison of rasagiline vs placebo was performed using the same model. The efficacy population (full analysis set) consisted of all randomized participants with baseline data and postrandomization endpoint data subsequent to $1 dose of study medication.
It was planned that approximately 1,000 participants (200 per treatment arm) would be randomized. Results from the TEMPO trial showed that rasagiline improved UPDRS 213 scores by approximately 3.5 points over placebo with a pooled standard deviation of 7.2 points. 26 Based on a literature review of recent clinical trials studying the same primary endpoint, the estimated SD was expected to be 9 points. Using a SD of 9 points and a 2-sided a 5 0.05, 200 participants in each arm provided at least 91% power to detect a clinically relevant difference of 3 points in UPDRS 213 scores between preladenant and placebo.
Key secondary endpoints were the proportion of responders (proportion of participants with at least a 20% improvement in UPDRS 213 from baseline at week 26) and change from baseline to week 26 in the UPDRS part 2 (UPDRS 2 ) score. Responder rates for each treatment arm are presented along with odds ratios (ORs) and 95% CIs for the ORs comparing preladenant dose groups with placebo. The change from baseline in the UPDRS 2 score was evaluated using the primary endpoint model.
Multiplicity for the preladenant vs placebo comparisons was controlled using an ordered testing procedure (see e-Methods at Neurology.org).
Post hoc investigations.
Once efficacy results of part 1 of the trial were known, a number of post hoc investigations were undertaken. The potential effect of caffeine consumption at baseline was evaluated by adding a caffeine term to the primary analysis model. Caffeine is a nonspecific adenosine receptor antagonist that has been speculated to have a protective effect in PD. 14, 27 Results were also analyzed according to geographic area, as this was found to have an influence on efficacy in a preladenant adjunct trial. 13 Classification of evidence. This study provides Class I evidence that for patients with early PD, preladenant is not effective as monotherapy at the doses studied (2, 5, 10 mg).
RESULTS Participants. Of 1,022 participants randomized, 1,007 were treated and 868 (86% of those treated) completed part 1 with discontinuations being similar across treatment groups (figure 1). Part 2 of the trial was terminated early after the results of part 1 were available and 2 phase 3 adjunctive treatment trials 13 failed to demonstrate superiority of preladenant over placebo (figure e-1).
Baseline characteristics were similar among treatment groups (table 1) . Approximately a third of participants in each treatment group took concomitant PD medications (table 1) . Of the PD medications used, 53% were amantadine, 27% were anticholinergics, 8% were dopamine agonists, 6% were L-dopa, and 7% were other types.
Efficacy. In part 1, neither preladenant nor rasagiline was superior to placebo in improving UPDRS 213 change from baseline score at week 26 (table 2) . Although there was a dose response for preladenant at all timepoints on the primary endpoint, and the efficacy of preladenant 10 mg appeared similar to rasagiline, the placebo arm had the highest improvement and therefore treatment differences vs placebo were not significant (figure 2). The secondary endpoints of the proportion of responders and UPDRS 2 change from baseline score at week 26 also showed no significant differences between preladenant or rasagiline vs placebo (table 2) . Due to the failure of preladenant in part 1 and the early termination of part 2 of the trial, no efficacy analyses were performed for part 2.
Safety. A summary of AEs during part 1 is shown in table e-1. AEs were reported by around 54%-59% of participants treated with preladenant and 52% of participants treated with either rasagiline or placebo. Relatively few participants discontinued due to AEs (preladenant 4%-10%, rasagiline 3%, placebo 4%).The most common AE with preladenant was headache (4%-7% vs 3% for placebo) and the most common AE with rasagiline was dizziness (5% vs 5% for placebo). One death was reported during part 1; a participant in the preladenant 10 mg group had a hemorrhagic vascular stroke, which was considered by the investigator to be unlikely to be related to study drug. A summary of AEs during part 2 is shown in table e-2. During part 2, around 68% of participants reported AEs across treatment arms, higher than in part 1 of the study. There were no striking differences between treatment groups. The most common AE with preladenant was headache (6%-10%) and the most common AE with rasagiline was dizziness (9%). One death was reported during part 2; a participant in the preladenant 10 mg group died from a sudden cardiac event, which was considered by the investigator to be unlikely to be related to study drug.
In part 1, ALT increases .3 3 the upper limit of normal (ULN) were preladenant 2 mg 5 1.0% (2/ 194), 5 mg 5 1.5% (3/198), 10 mg 5 4.6% (9/196), placebo 5 0% (0/193), and rasagiline 5 1.5% (3/ 195) . In part 2, rates were more similar in the preladenant and rasagiline arms: preladenant 2 mg 5 1.2% (2/165), 5 mg 5 1.2% (2/173), 10 mg 5 3.0% (5/164), placebo/preladenant 5 mg 5 0.6% (1/175), and rasagiline 5 2.3% (4/181). AST results were similar overall, but with a lower incidence of values . 3 3 ULN in both parts of the study. No Hy's Law cases were observed (a marker for clinical significance: ALT 3 3 ULN, alkaline phosphatase .2 3 ULN, and associated with an increase in bilirubin $2 3 ULN). 28 Post hoc efficacy analyses. Review of baseline participant characteristics did not reveal any notable differences between this and previous monotherapy trials (table e-3). There was a suggestion that baseline caffeine use was associated with UPDRS 213 change from baseline score, with .1 cup/d being associated with a significantly lower score than #1 cup/d, p 5 0.035. The association was not significant for $1 cup/d vs ,1 cup/d, p 5 0.532. Only a third of participants reported consuming .1 cup of caffeine per day (table 1) . Table 1 Baseline characteristics of randomized participants Prior use of L-dopa, n (%) 19 (9) 15 (7) 16 (8) 6 (3) 14 (7) Concomitant PD medication, n (%) Analyses of potential regional differences on UPDRS 213 change from baseline score found that Latin America and Eastern Europe had the strongest placebo response whereas the rasagiline response was strongest in North America and the European Union (table 3) . In a subgroup analysis by region, North America 1 European Union 1 India and Turkey showed results that were consistent with expectations of improvement for preladenant 10 mg and rasagiline vs placebo (figure e-2A) whereas neither preladenant 10 mg nor rasagiline differed from placebo in the Latin America 1 Eastern Europe subgroup (figure e-2B). Comparing across figures e-2A and e-2B, it can be seen that the absolute values for preladenant 10 mg and rasagiline were similar across the 2 regional subgroups while there was a striking difference in placebo response.
DISCUSSION The A 2a receptor antagonist preladenant when given as monotherapy in patients with early PD did not significantly improve UPDRS activities of daily living plus motor function scores compared to placebo. However, because the active control, rasagiline, also failed to demonstrate a significant improvement in UPDRS scores, it is not possible to determine whether these findings indicate inefficacy for preladenant or are related to issues of study conduct. The only other adequately sized monotherapy trial of a selective A 2A receptor antagonist to date also failed to demonstrate a significant effect of istradefylline. 16 Despite these discouraging results, it would be premature to conclude that A 2a receptor antagonists do not have efficacy as monotherapy. It is possible that problems with the execution of clinical trials have hindered our ability to demonstrate efficacy. This is supported by the failure of rasagiline in our study. Rasagiline improved UPDRS in 2 previous large monotherapy trials (TEMPO and ADAGIO) 26, 29 and its clinical efficacy is supported by other studies and observations. 17, 18 There are a number of difficulties in conducting large trials in de novo parkinsonian patients. Structural error (inappropriate study design, entry criteria, endpoints) or operational error (errors in diagnosis, inappropriate investigators, inadequate training with inconsistent evaluations, and aberrant or missing data) can lead to failure of a study. The present study used a placebo-controlled, active-comparator design that was similar to previous de novo trials, and the entry criteria as well as endpoints were similar to other de novo trials. It is possible that the relatively high chance of receiving active treatment in our trial of 80%, compared with, for example, 67% in the TEMPO trial 26 and 50% in the ADAGIO trial, 29 may have contributed to the high placebo response. Errors in diagnosis may occur in patients with early PD. Usually about 15% of participants enrolled in an early trial are eventually determined to have other diseases. The problem is further exacerbated in phase 3 trials, when more sites and participants are required than for smaller investigational trials, which can be performed at a few expert centers. However, this was also the case in studies with other treatments that found positive results. Moreover, we took steps to try to ensure accuracy of diagnosis (for example, a diagnosis based solely on bradykinesia and postural instability was considered insufficient) and special attention was paid to accurate diagnosis during the investigators meeting and with subsequent follow-up. Nevertheless, because of the large number of sites required for Table 3 Post hoc analysis: differences in UPDRS 213 score at week 26 by region (full analysis set) the trial, some less experienced investigators may have been selected, leading to an increase in wrong diagnosis and inaccurate evaluations. Another potential issue relates to the measures used to assess outcomes (UPDRS in this case). Assessments should be performed in a standardized manner by experienced raters to minimize variability. For this trial, a comprehensive UPDRS rater training and qualification program was utilized so all reasonable steps were taken. Although the UPDRS in not very sensitive in mildly affected patients, particularly with regard to early motor deficits, it was able to detect treatment benefits vs placebo in previous de novo trials.
An interesting finding emerged in our post hoc analyses of regional differences. We identified a large placebo effect in Latin America and Eastern Europe with numerically greater improvement in UPDRS scores in these regions in the placebo than the preladenant or rasagiline groups. The reason for this finding is not known but a large placebo response was also observed in a phase 3 adjunct trial of preladenant in Latin America and Eastern Europe compared to North America and the European Union. 13 Differences could potentially be due to clinical trials experience, cultural or language differences, genetic variation, or as yet unidentified reasons. In those regions in the present monotherapy trial where the placebo response was lowest (North America and the European Union), the rasagiline treatment difference vs placebo of 21.5 to 22.4 points was directionally in line with expectations, although still less than the 23.5 points the study was powered to detect and that has been proposed as a minimal clinically important change. 30 Furthermore, in those regions with lowest placebo response, preladenant showed a dose response in efficacy, with the highest 10 mg dose having similar efficacy to rasagiline (differences from placebo of 20.8 to 22.4 for preladenant 10 mg).
Another difficulty in interpreting the results from monotherapy trials is whether the appropriate doses were selected for evaluation. The doses of preladenant were chosen based on those used in the phase 2b adjunct study in patients with moderate to severe PD on L-dopa, which demonstrated that 5 and 10 mg were effective. There was no prior experience of preladenant in patients with early PD who were not receiving dopaminergic therapy to guide dose selection. History with many dopaminergic agents suggests that treatment doses for early disease are similar to adjunct therapy in patients with moderate to severe PD. However, it is possible that this might not be true for A 2A receptor antagonists.
Preladenant was generally well-tolerated in this trial, although the highest dose was associated with more AEs and discontinuations due to AEs than either placebo or rasagiline. Preladenant showed an increase in the percentage of patients with ALT increases but no Hy's Law cases, a marker for clinical significance, 28 were observed. The increase in AEs and ALT with preladenant, particularly the highest 10 mg dose, suggests that it was having biological activity despite the failure to demonstrate efficacy.
Our trial did not provide evidence that preladenant is effective as monotherapy in patients with early PD. The lack of efficacy on the primary endpoint of the active control, rasagiline, makes it difficult to interpret these results. Post hoc analyses suggest the possibility that some aspect of trial administration may have masked a potential drug effect. Definitive conclusions regarding the potential efficacy of preladenant specifically, and A 2a receptor antagonists as a class, as monotherapy in PD cannot be reached on the basis of this trial.
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